Organisation paid for research Program year 2025 Source: CMS Open Payments

Tennessee Oncology, PLLC

Neither a doctor nor a teaching hospital

Research payments

$6,080,490

1,020 payments

Through program year 2025, Tennessee Oncology, PLLC is reported as receiving $6,080,490 in research payments, across 1,020 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,002,919 29
2024 Research $1,022,391 25
2023 Research $246,212 12
2022 Research $199,979 13
2021 Research $1,522,864 177
2020 Research $1,418,878 682
2019 Research $667,248 82

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $3,241,692 216 payments
  2. Boehringer Ingelheim International GmbH $681,763 558 payments
  3. Sanofi US Services Inc. $662,956 6 payments
  4. Novartis Pharmaceuticals Corporation $380,022 14 payments
  5. Ipsen Biopharmaceuticals, Inc $358,933 5 payments
  6. Amgen Inc. $249,154 5 payments
  7. Celgene Corporation $159,229 6 payments
  8. E.R. Squibb & Sons, L.L.C. $134,440 7 payments
  9. Moderna TX, Inc. $100,395 10 payments
  10. Varian Medical Systems, Inc. $71,844 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma $857,042 41 payments
  2. IST- Tolerance Combination Dose-Carfilzomide-IV $662,956 6 payments
  3. A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in combination with Pembrolizumab in Patients with Advanced Malignancies $598,700 71 payments
  4. A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in combination with Pembrolizumab in Patients with Advanced Malignancies $559,975 29 payments
  5. A Phase 1,2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies $411,863 3 payments
  6. BI754111 & BI754091/BI75411 combination $297,512 287 payments
  7. A Phase II Study ofLanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 MicrospheresSIR-Spheres $249,921 3 payments
  8. A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma $248,671 1 payment
  9. A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer $220,732 2 payments
  10. Phase I study of BI 905681 $217,243 87 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record